| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Other | - | 5,535 | ||
| Right-of-use assets, net | - | 24,318 | ||
| Total other assets | - | 29,853 | ||
| Cash and cash equivalents | 6,308,420 | 6,936,620 | ||
| Prepaid expenses and other | 278,342 | 217,201 | ||
| Total current assets | 6,586,762 | 7,153,821 | ||
| Prepaid expenses | 993,701 | 993,701 | ||
| Total non-current assets | - | 993,701 | ||
| Property and equipment, net | 4,113 | 4,414 | ||
| Total assets | 7,584,576 | 8,181,789 | ||
| Accounts payable | 727,172 | 785,754 | ||
| Current maturities of lease liability | - | 25,584 | ||
| Accrued expenses | 1,023,806 | 1,263,243 | ||
| Total current liabilities | 1,750,978 | 2,074,581 | ||
| Non-current lease liability | - | 0 | ||
| Total liabilities | 1,750,978 | 2,074,581 | ||
| Common stock, par value 0.0001, 100,000,000 shares authorized 52,867,926 issued and 52,862,926 outstanding at september 30, 2025 and 3,707,628 issued and 3,702,628 outstanding at december 31, 2024 | 5,287 | 4,029 | ||
| Additional paid-in capital | 103,552,406 | 100,390,701 | ||
| Treasury stock, 5,000 shares, at cost | 300,000 | 300,000 | ||
| Accumulated deficit | -97,424,095 | -93,987,522 | ||
| Total stockholders equity | 5,833,598 | 6,107,208 | ||
| Total liabilities and stockholders equity | 7,584,576 | 8,181,789 | ||
Processa Pharmaceuticals, Inc. (PCSA)
Processa Pharmaceuticals, Inc. (PCSA)